Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,039 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: LCC Clear all
Completed No phase listed Observational

A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)

NCT01519232
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Liver Irradiation
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 28, 2026, 2:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Costa Mesa, California • La Jolla, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Recruiting Phase 1 Interventional

IDOV-Immune for Advanced Solid Tumors

NCT06910657
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

NCT01356628
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, HCC, Liver Cancer
Interventions
PD-0332991
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver

NCT00582400
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
arsenic trioxide
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

NCT03752398
View directory record Official record
Conditions
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
Interventions
XmAb®23104, Yervoy® (ipilimumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer

NCT01522937
View directory record Official record
Conditions
Liver Cancer, Hepatocellular Cancer
Interventions
individualized Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Not applicable Interventional Results available

Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT00293397
View directory record Official record
Conditions
Liver Cancer
Interventions
Drug-eluting beads loaded with doxorubicin hydrochloride
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated No phase listed Observational

Freehand Ultrasound Elasticity Imaging in Liver Surgery

NCT00942383
View directory record Official record
Conditions
Liver Tumors
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC

NCT00576056
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib, TACE
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 28, 2026, 2:32 AM EDT
Recruiting Not applicable Interventional

Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer

NCT06824974
View directory record Official record
Conditions
Liver Cancer, Adult, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Obesity and Overweight
Interventions
Time-restricted eating plus healthy diet
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 4 Interventional

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

NCT04288323
View directory record Official record
Conditions
Liver Cancer, Liver Cirrhoses, Liver Carcinoma
Interventions
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed No phase listed Observational

A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

NCT04763408
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Lenvatinib, Sorafenib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Pasadena, California • The Bronx, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 28, 2026, 2:32 AM EDT
Not yet recruiting Phase 2 Interventional

Erlotinib for Hepatocellular Carcinoma Chemoprevention

NCT04172779
View directory record Official record
Conditions
Cirrhosis, Liver, Advanced Liver Fibrosis
Interventions
erlotinib hydrochloride, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 2 Interventional

Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

NCT00003557
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions
dolastatin 10
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
11
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

NCT00604721
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
selumetinib, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Tampa, Florida • Atlanta, Georgia • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00010023
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, cisplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Oct 28, 2026, 2:32 AM EDT
Suspended Not applicable Interventional

Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation

NCT02935478
View directory record Official record
Conditions
Obesity, Weight Loss, Body Weight, Hepatocellular Carcinoma, HCC, Hepatitis C, Cirrhosis
Interventions
Embospheres Microspheres
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 28, 2026, 2:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

NCT05468359
View directory record Official record
Conditions
Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer, Pediatric Solid Tumor, Fibrolamellar Carcinoma
Interventions
Atezolizumab, Sorafenib, Bevacizumab, Cyclophosphamide
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
2
States / cities
Germantown, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed No phase listed Observational

A Retrospective Review of Malignant Liver Tumors

NCT00728650
View directory record Official record
Conditions
Liver Cancer
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
20 Years to 90 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 28, 2026, 2:32 AM EDT
Active, not recruiting Phase 3 Interventional

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

NCT03533582
View directory record Official record
Conditions
Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Patient Observation, Resection, Sorafenib, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
180
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

NCT02292173
View directory record Official record
Conditions
Hepatocellular Cancer, Liver Cancer
Interventions
Trametinib, Sorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 28, 2026, 2:32 AM EDT